TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Up 78.2% in September

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) saw a significant growth in short interest in the month of September. As of September 30th, there was short interest totaling 918,500 shares, a growth of 78.2% from the September 15th total of 515,400 shares. Based on an average trading volume of 101,200 shares, the days-to-cover ratio is currently 9.1 days. Approximately 5.7% of the shares of the company are short sold. Approximately 5.7% of the shares of the company are short sold. Based on an average trading volume of 101,200 shares, the days-to-cover ratio is currently 9.1 days.

TriSalus Life Sciences Price Performance

Shares of TLSI stock opened at $5.14 on Wednesday. The company has a market cap of $256.33 million, a price-to-earnings ratio of -4.36 and a beta of 0.47. The stock has a 50 day simple moving average of $4.80 and a 200-day simple moving average of $5.00. TriSalus Life Sciences has a 1-year low of $3.42 and a 1-year high of $5.88.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.05). The firm had revenue of $11.21 million during the quarter, compared to analyst estimates of $10.69 million. TriSalus Life Sciences has set its FY 2025 guidance at EPS. Analysts anticipate that TriSalus Life Sciences will post -1.55 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on TLSI shares. Weiss Ratings reissued a “sell (d-)” rating on shares of TriSalus Life Sciences in a report on Wednesday, October 8th. Wall Street Zen downgraded TriSalus Life Sciences from a “hold” rating to a “sell” rating in a report on Sunday, September 28th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $10.90.

Institutional Trading of TriSalus Life Sciences

Large investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. purchased a new stake in shares of TriSalus Life Sciences during the first quarter worth approximately $55,000. Goldman Sachs Group Inc. purchased a new stake in shares of TriSalus Life Sciences during the first quarter worth approximately $187,000. Gilder Gagnon Howe & Co. LLC increased its position in shares of TriSalus Life Sciences by 32.1% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock worth $5,957,000 after purchasing an additional 265,618 shares in the last quarter. Geode Capital Management LLC increased its position in shares of TriSalus Life Sciences by 107.4% during the second quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock worth $2,480,000 after purchasing an additional 235,627 shares in the last quarter. Finally, Bank of America Corp DE increased its position in shares of TriSalus Life Sciences by 1.8% during the second quarter. Bank of America Corp DE now owns 188,906 shares of the company’s stock worth $1,030,000 after purchasing an additional 3,374 shares in the last quarter. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.